Eculizumab Experince at a Patient With Atypical Hemolitic Uremic Syndrome

Abstract

Thrombotic microangiopathy discribes a specific pathologic lesion in which abnormalities in the vessel wall of arterioles and capillaries lead to microvascular thrombosis. Microangiopathic hemolytic anemia is a descriptive term for non-immun hemolytic anemia resulting from intravascular red blood cell fragmentation that produces schistocytes on the peripheral blood smear. Atypical hemolytic uremic syndrome is a type of primer thrombotic microangiopathy and using eculizumab in the early phase of therapy reduces the risk of irreversible renal damage. We mentioned both the importance of early diagnosis at the patients presenting with microangiopathic hemolytic anemia and thrombocytopenia like our patient and the benefit of eculizumab therapy at the early phase of atypical hemolytic uremic syndrome therapy.